FibroGen, Inc. (FGEN)

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), today announced that the data on anti-tumor activity of FG-3246 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) from the investigator-sponsored Phase 1b/2 study will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026 in San Francisco, CA.

FibroGen, Inc (NASDAQ: FGEN - Get Free Report) shares crossed above its 50 day moving average during trading on Friday. The stock has a 50 day moving average of $8.96 and traded as high as $9.75. FibroGen shares last traded at $9.77, with a volume of 31,125 shares trading hands. Analyst Ratings Changes Separately, Weiss

SAN FRANCISCO, Jan. 07, 2026 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), today announced it is rebranding the company to Kyntra Bio, representing the next step of the transformation of the Company and its focus on oncology and rare disease assets. The Company's common stock will begin trading under the new Nasdaq symbol “KYNB” at stock market open on January 8, 2026.

FibroGen, Inc. ( FGEN ) Q3 2025 Earnings Call November 10, 2025 5:00 PM EST Company Participants Thane Wettig - CEO & Director David DeLucia - Senior VP & CFO Conference Call Participants Gaia Vasiliver-Shamis Andy Hsieh Matthew Keller - H.C. Wainwright & Co, LLC, Research Division Chen Lin Presentation Operator Hello, and thank you for standing by.

FibroGen (FGEN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $4.01. This compares to a loss of $4.25 per share a year ago.

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

SAN FRANCISCO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the initiation of the Phase 2 monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46-expressing cancer lesions in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial will also assess the diagnostic and predictive performance of FG-3180, a companion PET imaging agent, which shares the same CD46-targeted antibody used in FG-3246. The ability of FG-3180 to identify mCRPC lesions and predict response to FG-3246 will be evaluated.

SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY.

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025.

FibroGen, Inc. (NASDAQ:FGEN ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Carol Gaddum - Corporate Participant Product Team Lead - Corporate Participant David DeLucia - Chief Financial Officer Thane Wettig - CEO & Director Conference Call Participants Matthew Keller - H.C. Wainwright & Co, LLC, Research Division Tsan-Yu Hsieh - William Blair & Company L.L.C.

FibroGen (FGEN) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $2.25. This compares to a loss of $4 per share a year ago.

SAN FRANCISCO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the second quarter 2025 and provided an update on the company's recent developments.

SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

U.S. stock futures were lower this morning, with the Dow futures falling more than 500 points on Friday.

SAN FRANCISCO, June 12, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that it will implement a 1-for-25 reverse stock split of its issued and outstanding common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. FibroGen's common stock will begin trading on a split-adjusted basis on June 17, 2025, when the markets open, under the Company's existing trading symbol “FGEN,” with the new CUSIP number 31572Q881.

SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Dr. Michael Kauffman to its Board of Directors effective June 4, 2025.